MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-179218 | Pharmaceuticals and Medical
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Molecular Human Papillomavirus (Hpv) Diagnostic Equipment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET
7.1 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA MOLECULAR HUMAN PAPILLOMAVIRUS (HPV) DIAGNOSTIC EQUIPMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 F Hoffmann-La Roche Ltd
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Agilent Technologies, Inc
16.3 Becton, Dickinson and Company
16.4 Qiagen NV
16.5 Thermo Fisher Scientific Inc
16.6 Abbott Laboratories
16.7 Hologic Inc
16.8 Cepheid Inc
16.9 Seegene Inc
16.10 Takara Bio Inc
16.11 DaAn Gene Co, Ltd of Sun Yat-Sen University
16.12 Promega Corporation
16.13 Greiner Bio-One International GmbH (Greiner Holding AG)
16.14 Enzo Biochem Inc
16.15 Norgen Biotek Corp
16.16 DiagCor Bioscience Inc Ltd
16.17 Hybribio Limited
16.18 Zytovision GmbH
16.19 Arbor Vita Corporation
16.20 Medical & Biological Laboratories Co, Ltd
16.21 Fujirebio Diagnostics, Inc
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeServices
Assay kits
System
By Application
Hosptial
Clinic
Companies
F Hoffmann-La Roche Ltd
Agilent Technologies, Inc
Becton, Dickinson and Company
Qiagen NV
Thermo Fisher Scientific Inc
Abbott Laboratories
Hologic Inc
Cepheid Inc
Seegene Inc
Takara Bio Inc
DaAn Gene Co, Ltd of Sun Yat-Sen University
Promega Corporation
Greiner Bio-One International GmbH (Greiner Holding AG)
Enzo Biochem Inc
Norgen Biotek Corp
DiagCor Bioscience Inc Ltd
Hybribio Limited
Zytovision GmbH
Arbor Vita Corporation
Medical & Biological Laboratories Co, Ltd
Fujirebio Diagnostics, Inc
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.